



Pádraig O'Sullivan, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

27th July 2023

PQ: 33836/23

To ask the Minister for Health the level of drawdown on the €30 million announced for new medicines as part of Budget 2022, inclusive of acute spending and described on an in-year basis; and if he will make a statement on the matter. -Pádraig O'Sullivan

Dear Deputy O'Sullivan,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 33836/23), which you submitted to the Minister for Health for response.

During 2022, a total of 60 new medicines were approved by the HSE, 30 of which are new medicines while 30 are licence extensions/new uses of existing medicines. 36 of these medicines were approved on a cost-minimisation basis relative to existing therapies (i.e. an uplift in pharmaceutical expenditure will not be incurred for those medicines as they have demonstrated budget neutrality). The remaining 24 of drugs approved fall within the €30m allocation announced for new medicines as part of Budget 2022. The Gross reimbursement by PCRS in 2022 for 2022 New Drugs which fall into the €30m new drug allocation was €9.4m and the Gross reimbursement by PCRS June 2023 YTD for the 2022 New Drugs which fall into said €30m allocation is €15.32m.

** Sources:-PCRS December 2022 Performance Report & PCRS June 2023 Performance Reports.

Yours sincerely,

A handwritten signature in black ink that reads 'Suzanne Doyle'.

Suzanne Doyle

Primary Care Eligibility & Reimbursement Service